Choosing wisely: The Canadian rheumatology association's list of 5 items physicians and patients should question

Journal of Rheumatology

Volumn 42, Issue 4, 2015, Pages 682-689

  Chow, Shirley L ^a   Thorne, J Carter ^b   Bell, Mary J ^a   Ferrari, Robert ^c   Bagheri, Zarnaz ^a   Boyd, Tristan ^d   Colwill, Ann Marie ^e   Jung, Michelle ^d   Frackowiak, Damian ^a   Hazlewood, Glen S ^f   Kuriya, Bindee ^a   Tugwell, Peter ^g  

^a UNIVERSITY OF TORONTO   (Canada)

^b SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d WESTERN UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Clinical practice guideline; Cost benefit analysis; Cost effectiveness; Rheumatology

Indexed keywords

ANTINUCLEAR ANTIBODY; BISPHOSPHONIC ACID DERIVATIVE; HLA B27 ANTIGEN;

ARTICLE; BONE DENSITY; BONE DISEASE; BONE SCINTISCANNING; CANADA; DELPHI STUDY; DRUG USE; EVIDENCE BASED MEDICINE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PERSONNEL; HEALTH PRACTITIONER; HEALTH SURVEY; HUMAN; IMMUNOLOGICAL PROCEDURES; MEDICAL CARE; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL SOCIETY; METHODOLOGY; PATIENT CARE; PATIENT DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOLOGY; SEX; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; ECONOMICS; RHEUMATIC DISEASES;

CANADA; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; HUMANS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 84940436944     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.141140     Document Type: Article

References (57)

1. Canadian Institute for Health Information. Health spending in Canada in 2013. [Internet. Accessed December 22, 2014. ] Available from: www. cihi. ca/CIHI-ext-portal/internet/en/document/spending+ and+health+workforce/spending/release-29oct13-infogra1pg
2. Dartmouth Medical School Center for the Evaluative Clinical Sciences. The care of patients with severe chronic illness: an online report on the Medicare Program by the Dartmouth Atlas Project. [Internet. Accessed December 22, 2014. ] Available from: www. dartmouthatlas. org/downloads/atlases/2006-Chronic- Care-Atlas. pdf
3. Kale MS, Bishop TF, Federman AD, Keyhani S. Top 5 lists top 5 billion. Arch Intern Med 2011;171:1858-9.
4. Welch HG, Schwartz L, Woloshin S. Overdiagnosed: making people sick in the pursuit of health. Boston: Beacon Press; 2011.
5. Choosing Wisely Canada. Canadian Rheumatology Association: five things physicians and patients should question. [Internet. Accessed December 22, 2014. ] Available from: www. choosingwiselycanada. org/recommendations/ canadian-rheumatology-association-2/
6. Choosing Wisely: an initiative of the ABIM [Internet. Accessed December 22, 2014. ] Available from: www. choosingwisely. org
7. Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A, Yelin E, et al. Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question. Arthritis Care Res 2013;65:329-39.
8. Linstone HA, Turoff M. The Delphi method: techniques and applications. Massachusetts: Addison-Wesley Educational Publishers Inc. ; 1975.
9. Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012;39:1559-82.
10. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 2000;124:71-81.
11. British Columbia Ministry of Health. Antinuclear antibody (ANA) testing for connective tissue disease. [Internet. Accessed December 23, 2014. ]. Available from: www. bcguidelines. ca/guideline-ana-testing. html
12. Solomon DH, Kavanaugh AJ, Schur PH ; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002;47:434-44.
13. Tozzoli R, Bizzaro N, Tonutti E, Villalta D, Bassetti D, Manoni F, et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 2002;117:316-24.
14. Man A, Shojania K, Phoon C, Pal J, de Badyn MH, Pi D, et al. An evaluation of autoimmune antibody testing patterns in a Canadian health region and an evaluation of a laboratory algorithm aimed at reducing unnecessary testing. Clin Rheumatol 2013;32:601-8.
15. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014;73:17-23.
16. Suarez-Almazor ME, Gonzalez-Lopez L, Gamez-Nava JI, Belseck E, Kendall CJ, Davis P. Utilization and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians. J Rheumatol 1998;25:1980-5.
17. Callado MR, de Alencar Barroso MN, Alves VM, de Lima Abreu MA, Muniz LM, Lima JR. Antinuclear antibodies: two-step detection strategy. Immunol Invest 2014;43:86-95.
18. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
19. Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapää-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011;13:R30.
20. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83.
21. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25-31.
22. Sidiropoulos PI, Hatemi G, Song IH, Avouac J, Collantes E, Hamuryudan V, et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology 2008;47:355-61.
23. Rostom S, Dougados M, Gossec L. New tools for diagnosing spondyloarthropathy. Joint Bone Spine 2010;77:108-14.
24. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369:1379-90.
25. van den Berg R, van der Heijde DM. How should we diagnose spondyloarthritis according to the ASAS classification criteria: a guide for practicing physicians. Pol Arch Med Wewn 2010;120:452-7.
26. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004;63:535-43.
27. Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. Curr Opin Rheumatol 2010;22:375-80.
28. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-73.
29. The International Society for Clinical Densitometry. Official positions of the ISCD 2013. [Internet. Accessed December 22, 2014. ] Available from: www. iscd. org/documents/2013/07/ 2013-iscd-official-positions-adult. pdf
30. U. S. Preventive Services Task Force. Screening for osteoporosis: U. S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2011;154:356-64.
31. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010;16 Suppl 3:1-37.
32. Frost SA, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Timing of repeat BMD measurements: development of an absolute risk-based prognostic model. J Bone Miner Res 2009;24:1800-7.
33. Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui L, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 2012;366:255-33.
34. Hillier TA, Stone KL, Bauer DC, Rizzo JH, Pedula KL, Cauley JA, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med 2007;167:155-60.
35. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9.
36. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008: CD001155.
37. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; CD003376.
38. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; CD004523.
39. FRAX: Fracture Risk Assessment Tool. Calculation tool. [Internet. Accessed December 22, 2014. ] Available from: www. sheffield. ac. uk/FRAX/tool. jsp?country=19
40. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. [Internet. Accessed December 23, 2014. ] Available from: nof. org/hcp/clinicians-guide
41. Geusens P. Strategies for treatment to prevent fragility fractures in postmenopausal women. Best Pract Res Clin Rheumatol 2009;23:727-40.
42. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. How to decide who to treat. Best Pract Res Clin Rheumatol 2009;23:711-26.
43. Eriksen EF. Treatment of osteopenia. Rev Endocr Metab Disord 2012;13:209-23.
44. Eastell R, Walsh JS, Watts NB, Siris E. Bisphosphonates for postmenopausal osteoporosis. Bone 2011;49:82-8.
45. Roux C. Osteopenia: is it a problem? Int J Clin Rheumtol 2009;4:651-5.
46. Neuner JM, Laud PW, Schapira MM. A randomized study of the effect of 5-year and lifetime hip fracture risk information on physician recommendations for management of low bone density. J Clin Densitom 2007;10:370-5.
47. Neuner JM, Schapira MM. The importance of physicians' risk perception in osteoporosis treatment decision making. J Clin Densitom 2012;15:49-54.
48. Neuner JM, Schapira MM. Patient perceptions of osteoporosis treatment thresholds. J Rheumatol 2013;41:516-22.
49. Fisher BA, Frank JW, Taylor PC. Do Tc-99m-diphosphonate bone scans have any place in the investigation of polyarthralgia? Rheumatology 2007;46:1036-7.
50. Whallett A, Evans N, Bradley S, Jobanputra P. Isotope bone scans: an assessment of their diagnostic use in polyarticular pain of uncertain origin. Ann Rheum Dis 2003;62:784-5.
51. Picano E, Matucci-Cerinic M. Unnecessary radiation exposure from medical imaging in the rheumatology patient. Rheumatology 2011;50:1537-9.
52. Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008;248:254-63.
53. Song IH, Carrasco-Fernández J, Rudwaleit M, Sieper J. The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis 2008;67:1535-40.
54. Campbell EG, Regan S, Gruen RL, Ferris TG, Rao SR, Cleary PD, et al. Professionalism in medicine: results of a national survey of physicians. Ann Intern Med 2007;147:795-802.
55. Brett AS, McCullough LB. Addressing requests by patients for nonbeneficial interventions. JAMA 2012;307:149-50.
56. Tilburt JC, Wynia MK, Sheeler RD, Thorsteinsdottir B, James KM, Egginton JS, et al. Views of US physicians about controlling health care costs. JAMA 2013;310:380-8.
57. Emanuel EJ, Steinmetz A. Will physicians lead on controlling health care costs? JAMA 2013;310:374-5.